Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study

S. De Placido, C. Gallo, F. Perrone, A. Marinelli, C. Pagliarulo, C. Carlomagno, G. Petrella, M. D'Istria, G. Delrio, A. R. Bianco

Research output: Contribution to journalArticle

Abstract

The correlation between prolactin (PRLR) and oestrogen (ER) or progesterone receptors (PgR) in breast cancer and a possible prognostic significance of PRLR at 10 year follow-up have been investigated in the Naples (GUN) adjuvant trial. A total of 308 pre- and post-menopausal patients with early breast cancer, who entered the trial from 1 February 1978 to 31 December 1983, received randomly Tamoxifen (TM), 30 mg per die for 2 years, or no therapy. PRLR status was known in 229 (74.3%) patients. Values of specific binding less than 1% were considered negative. PRLR was positive in 75/229 (32.8%). ER was assayed in 210/229 (91.7%) patients and PgR in 188/229 (82.1%). No significant correlation, by the Spearman test, was found between PRLR and ER or PgR, while ER status was highly interrelated with PgR status. By the Cox model no evidence of an independent prognostic role of PRLR on disease-free survival (DFS) was observed, nor an interaction between PRLR and adjuvant treatment with TM was found.

Original languageEnglish
Pages (from-to)643-646
Number of pages4
JournalBritish Journal of Cancer
Volume62
Issue number4
Publication statusPublished - 1990

Fingerprint

Prolactin Receptors
Progesterone Receptors
Estrogen Receptors
Breast Neoplasms
Tamoxifen
Proportional Hazards Models
Prolactin
Disease-Free Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study. / De Placido, S.; Gallo, C.; Perrone, F.; Marinelli, A.; Pagliarulo, C.; Carlomagno, C.; Petrella, G.; D'Istria, M.; Delrio, G.; Bianco, A. R.

In: British Journal of Cancer, Vol. 62, No. 4, 1990, p. 643-646.

Research output: Contribution to journalArticle

De Placido, S, Gallo, C, Perrone, F, Marinelli, A, Pagliarulo, C, Carlomagno, C, Petrella, G, D'Istria, M, Delrio, G & Bianco, AR 1990, 'Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study', British Journal of Cancer, vol. 62, no. 4, pp. 643-646.
De Placido, S. ; Gallo, C. ; Perrone, F. ; Marinelli, A. ; Pagliarulo, C. ; Carlomagno, C. ; Petrella, G. ; D'Istria, M. ; Delrio, G. ; Bianco, A. R. / Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study. In: British Journal of Cancer. 1990 ; Vol. 62, No. 4. pp. 643-646.
@article{8e04cf59b2964092b02cb2d08a501b28,
title = "Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study",
abstract = "The correlation between prolactin (PRLR) and oestrogen (ER) or progesterone receptors (PgR) in breast cancer and a possible prognostic significance of PRLR at 10 year follow-up have been investigated in the Naples (GUN) adjuvant trial. A total of 308 pre- and post-menopausal patients with early breast cancer, who entered the trial from 1 February 1978 to 31 December 1983, received randomly Tamoxifen (TM), 30 mg per die for 2 years, or no therapy. PRLR status was known in 229 (74.3{\%}) patients. Values of specific binding less than 1{\%} were considered negative. PRLR was positive in 75/229 (32.8{\%}). ER was assayed in 210/229 (91.7{\%}) patients and PgR in 188/229 (82.1{\%}). No significant correlation, by the Spearman test, was found between PRLR and ER or PgR, while ER status was highly interrelated with PgR status. By the Cox model no evidence of an independent prognostic role of PRLR on disease-free survival (DFS) was observed, nor an interaction between PRLR and adjuvant treatment with TM was found.",
author = "{De Placido}, S. and C. Gallo and F. Perrone and A. Marinelli and C. Pagliarulo and C. Carlomagno and G. Petrella and M. D'Istria and G. Delrio and Bianco, {A. R.}",
year = "1990",
language = "English",
volume = "62",
pages = "643--646",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study

AU - De Placido, S.

AU - Gallo, C.

AU - Perrone, F.

AU - Marinelli, A.

AU - Pagliarulo, C.

AU - Carlomagno, C.

AU - Petrella, G.

AU - D'Istria, M.

AU - Delrio, G.

AU - Bianco, A. R.

PY - 1990

Y1 - 1990

N2 - The correlation between prolactin (PRLR) and oestrogen (ER) or progesterone receptors (PgR) in breast cancer and a possible prognostic significance of PRLR at 10 year follow-up have been investigated in the Naples (GUN) adjuvant trial. A total of 308 pre- and post-menopausal patients with early breast cancer, who entered the trial from 1 February 1978 to 31 December 1983, received randomly Tamoxifen (TM), 30 mg per die for 2 years, or no therapy. PRLR status was known in 229 (74.3%) patients. Values of specific binding less than 1% were considered negative. PRLR was positive in 75/229 (32.8%). ER was assayed in 210/229 (91.7%) patients and PgR in 188/229 (82.1%). No significant correlation, by the Spearman test, was found between PRLR and ER or PgR, while ER status was highly interrelated with PgR status. By the Cox model no evidence of an independent prognostic role of PRLR on disease-free survival (DFS) was observed, nor an interaction between PRLR and adjuvant treatment with TM was found.

AB - The correlation between prolactin (PRLR) and oestrogen (ER) or progesterone receptors (PgR) in breast cancer and a possible prognostic significance of PRLR at 10 year follow-up have been investigated in the Naples (GUN) adjuvant trial. A total of 308 pre- and post-menopausal patients with early breast cancer, who entered the trial from 1 February 1978 to 31 December 1983, received randomly Tamoxifen (TM), 30 mg per die for 2 years, or no therapy. PRLR status was known in 229 (74.3%) patients. Values of specific binding less than 1% were considered negative. PRLR was positive in 75/229 (32.8%). ER was assayed in 210/229 (91.7%) patients and PgR in 188/229 (82.1%). No significant correlation, by the Spearman test, was found between PRLR and ER or PgR, while ER status was highly interrelated with PgR status. By the Cox model no evidence of an independent prognostic role of PRLR on disease-free survival (DFS) was observed, nor an interaction between PRLR and adjuvant treatment with TM was found.

UR - http://www.scopus.com/inward/record.url?scp=0025052112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025052112&partnerID=8YFLogxK

M3 - Article

C2 - 2223582

AN - SCOPUS:0025052112

VL - 62

SP - 643

EP - 646

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -